The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group

Prakash Chinnaiyan, Meihua Wang, Amyn Mohammed Rojiani, Philip J. Tofilon, Arnab Chakravarti, K. Kian Ang, Hua Zhong Zhang, Elizabeth Hammond, Walter Curran, Minesh P. Mehta

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Nestin is an intermediate filament protein that has been implicated in early stages of neuronal lineage commitment. Based on the heterogeneous expression of nestin in GBM and its potential to serve as a marker for a dedifferentiated, and perhaps more aggressive phenotype, the Radiation Therapy Oncology Group (RTOG) sought to determine the prognostic value of nestin expression in newly diagnosed GBM patients treated on prior prospective RTOG clinical trials. Methods: Tissue microarrays were prepared from 156 patients enrolled in these trials. These specimens were stained using a mouse monoclonal antibody specific for nestin and expression was measured by computerized quantitative image analysis using the Ariol SL-50 system. The parameters measured included both staining intensity and the relative area of expression within a specimen. This resulted into 3 categories: low, intermediate, and high nestin expression, which was then correlated with clinical outcome. Results: A total of 153 of the 156 samples were evaluable for this study. There were no statistically significant differences between pretreatment patient characteristics and nestin expression. There was no statistically significant difference in either overall survival or progression-free survival (PFS) demonstrated, although a trend in decreased PFS was observed with high nestin expression (p = 0.06). Conclusion: Although the correlation of nestin expression and histologic grade in glioma is of considerable interest, the presented data does not support its prognostic value in newly diagnosed GBM. Further studies evaluating nestin expression may be more informative when studied in lower grade glioma, in the context of markers more specific to tumor stem cells, and using more recent specimens from patients treated with temozolomide in conjunction with radiation.

Original languageEnglish (US)
Article number32
JournalRadiation Oncology
Volume3
Issue number1
DOIs
StatePublished - Sep 25 2008

Fingerprint

Nestin
Radiation Oncology
Glioblastoma
Radiotherapy
temozolomide
Glioma
Disease-Free Survival
Intermediate Filament Proteins
Neoplastic Stem Cells
Monoclonal Antibodies
Clinical Trials
Radiation
Staining and Labeling
Phenotype
Survival

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

The prognostic value of nestin expression in newly diagnosed glioblastoma : Report from the Radiation Therapy Oncology Group. / Chinnaiyan, Prakash; Wang, Meihua; Rojiani, Amyn Mohammed; Tofilon, Philip J.; Chakravarti, Arnab; Ang, K. Kian; Zhang, Hua Zhong; Hammond, Elizabeth; Curran, Walter; Mehta, Minesh P.

In: Radiation Oncology, Vol. 3, No. 1, 32, 25.09.2008.

Research output: Contribution to journalArticle

Chinnaiyan, P, Wang, M, Rojiani, AM, Tofilon, PJ, Chakravarti, A, Ang, KK, Zhang, HZ, Hammond, E, Curran, W & Mehta, MP 2008, 'The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group', Radiation Oncology, vol. 3, no. 1, 32. https://doi.org/10.1186/1748-717X-3-32
Chinnaiyan, Prakash ; Wang, Meihua ; Rojiani, Amyn Mohammed ; Tofilon, Philip J. ; Chakravarti, Arnab ; Ang, K. Kian ; Zhang, Hua Zhong ; Hammond, Elizabeth ; Curran, Walter ; Mehta, Minesh P. / The prognostic value of nestin expression in newly diagnosed glioblastoma : Report from the Radiation Therapy Oncology Group. In: Radiation Oncology. 2008 ; Vol. 3, No. 1.
@article{b81fb38cedbf4a28a5a5072aacd50941,
title = "The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group",
abstract = "Background: Nestin is an intermediate filament protein that has been implicated in early stages of neuronal lineage commitment. Based on the heterogeneous expression of nestin in GBM and its potential to serve as a marker for a dedifferentiated, and perhaps more aggressive phenotype, the Radiation Therapy Oncology Group (RTOG) sought to determine the prognostic value of nestin expression in newly diagnosed GBM patients treated on prior prospective RTOG clinical trials. Methods: Tissue microarrays were prepared from 156 patients enrolled in these trials. These specimens were stained using a mouse monoclonal antibody specific for nestin and expression was measured by computerized quantitative image analysis using the Ariol SL-50 system. The parameters measured included both staining intensity and the relative area of expression within a specimen. This resulted into 3 categories: low, intermediate, and high nestin expression, which was then correlated with clinical outcome. Results: A total of 153 of the 156 samples were evaluable for this study. There were no statistically significant differences between pretreatment patient characteristics and nestin expression. There was no statistically significant difference in either overall survival or progression-free survival (PFS) demonstrated, although a trend in decreased PFS was observed with high nestin expression (p = 0.06). Conclusion: Although the correlation of nestin expression and histologic grade in glioma is of considerable interest, the presented data does not support its prognostic value in newly diagnosed GBM. Further studies evaluating nestin expression may be more informative when studied in lower grade glioma, in the context of markers more specific to tumor stem cells, and using more recent specimens from patients treated with temozolomide in conjunction with radiation.",
author = "Prakash Chinnaiyan and Meihua Wang and Rojiani, {Amyn Mohammed} and Tofilon, {Philip J.} and Arnab Chakravarti and Ang, {K. Kian} and Zhang, {Hua Zhong} and Elizabeth Hammond and Walter Curran and Mehta, {Minesh P.}",
year = "2008",
month = "9",
day = "25",
doi = "10.1186/1748-717X-3-32",
language = "English (US)",
volume = "3",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - The prognostic value of nestin expression in newly diagnosed glioblastoma

T2 - Report from the Radiation Therapy Oncology Group

AU - Chinnaiyan, Prakash

AU - Wang, Meihua

AU - Rojiani, Amyn Mohammed

AU - Tofilon, Philip J.

AU - Chakravarti, Arnab

AU - Ang, K. Kian

AU - Zhang, Hua Zhong

AU - Hammond, Elizabeth

AU - Curran, Walter

AU - Mehta, Minesh P.

PY - 2008/9/25

Y1 - 2008/9/25

N2 - Background: Nestin is an intermediate filament protein that has been implicated in early stages of neuronal lineage commitment. Based on the heterogeneous expression of nestin in GBM and its potential to serve as a marker for a dedifferentiated, and perhaps more aggressive phenotype, the Radiation Therapy Oncology Group (RTOG) sought to determine the prognostic value of nestin expression in newly diagnosed GBM patients treated on prior prospective RTOG clinical trials. Methods: Tissue microarrays were prepared from 156 patients enrolled in these trials. These specimens were stained using a mouse monoclonal antibody specific for nestin and expression was measured by computerized quantitative image analysis using the Ariol SL-50 system. The parameters measured included both staining intensity and the relative area of expression within a specimen. This resulted into 3 categories: low, intermediate, and high nestin expression, which was then correlated with clinical outcome. Results: A total of 153 of the 156 samples were evaluable for this study. There were no statistically significant differences between pretreatment patient characteristics and nestin expression. There was no statistically significant difference in either overall survival or progression-free survival (PFS) demonstrated, although a trend in decreased PFS was observed with high nestin expression (p = 0.06). Conclusion: Although the correlation of nestin expression and histologic grade in glioma is of considerable interest, the presented data does not support its prognostic value in newly diagnosed GBM. Further studies evaluating nestin expression may be more informative when studied in lower grade glioma, in the context of markers more specific to tumor stem cells, and using more recent specimens from patients treated with temozolomide in conjunction with radiation.

AB - Background: Nestin is an intermediate filament protein that has been implicated in early stages of neuronal lineage commitment. Based on the heterogeneous expression of nestin in GBM and its potential to serve as a marker for a dedifferentiated, and perhaps more aggressive phenotype, the Radiation Therapy Oncology Group (RTOG) sought to determine the prognostic value of nestin expression in newly diagnosed GBM patients treated on prior prospective RTOG clinical trials. Methods: Tissue microarrays were prepared from 156 patients enrolled in these trials. These specimens were stained using a mouse monoclonal antibody specific for nestin and expression was measured by computerized quantitative image analysis using the Ariol SL-50 system. The parameters measured included both staining intensity and the relative area of expression within a specimen. This resulted into 3 categories: low, intermediate, and high nestin expression, which was then correlated with clinical outcome. Results: A total of 153 of the 156 samples were evaluable for this study. There were no statistically significant differences between pretreatment patient characteristics and nestin expression. There was no statistically significant difference in either overall survival or progression-free survival (PFS) demonstrated, although a trend in decreased PFS was observed with high nestin expression (p = 0.06). Conclusion: Although the correlation of nestin expression and histologic grade in glioma is of considerable interest, the presented data does not support its prognostic value in newly diagnosed GBM. Further studies evaluating nestin expression may be more informative when studied in lower grade glioma, in the context of markers more specific to tumor stem cells, and using more recent specimens from patients treated with temozolomide in conjunction with radiation.

UR - http://www.scopus.com/inward/record.url?scp=53549099123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53549099123&partnerID=8YFLogxK

U2 - 10.1186/1748-717X-3-32

DO - 10.1186/1748-717X-3-32

M3 - Article

C2 - 18817556

AN - SCOPUS:53549099123

VL - 3

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 32

ER -